Injunction halts Apotex sales of generic Plavix in Sanofi-Aventis, Bristol-Myers Squibb patent case

By E. Janene Geiss

Philadelphia, Sept. 1 - Sanofi-Aventis and Bristol-Myers Squibb said Friday that the U.S. District Court for the Southern District of New York has granted a preliminary injunction ordering Apotex Inc. to halt its sales of a generic version of clopidogrel bisulfate product that competes with Plavix.

The court did not order the Weston, Ont., company to recall products already sold or shipped, according to a company new release.

The order was entered in connection with the patent infringement lawsuit relating to the validity of a composition of matter patent for clopidogrel bisulfate. Apotex launched Aug. 8 a generic version of clopidogrel bisulfate 75 mg tablets.

The injunction will remain in effect until the pending patent infringement lawsuit is resolved. Paris-based Sanofi-Aventis and New York-based Bristol-Myers Squibb said they believe the generic product infringes their intellectual property rights, which are the subject of the pending patent litigation. A trial has been set for Jan. 22, 2007.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.